Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 3/20 | 0.36 |
| ▸ | EP300 | Q09472 | 2/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | BID | P55957 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.36 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.36 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.36 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | JUN | P05412 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14684825 | 0.86 | GAA (0.44) | GAAMAPTKDM4EMCL1ALDH1A1 | |
| SCHEMBL129735 | 0.84 | MAPT (0.40) | GAAMAPTKDM4EMCL1KAT8 | |
| SCHEMBL69199 | 0.81 | HPGD (0.41) | GAAMAPTKDM4EMCL1HTR1A | |
| SCHEMBL27474264 | 0.80 | MAPT (0.40) | GAAMAPTKDM4EMCL1KAT8 | |
| SCHEMBL27341878 | 0.79 | SIGMAR1 (0.47) | MCL1BIDBCL2L1BAK1 | |
| SCHEMBL27523521 | 0.79 | MGLL (0.44) | MCL1HTR1AKAT8EP300KAT2B | |
| SCHEMBL28183541 | 0.78 | GAA (0.39) | GAAMAPTKDM4EHTR1AALDH1A1 | |
| SCHEMBL28184388 | 0.77 | GAA (0.38) | GAAMAPTKDM4EHTR1AALDH1A1 | |
| SCHEMBL27340483 | 0.76 | IGF1R (0.39) | KDM4EKAT8EP300HTR2AKAT5 | |
| SCHEMBL1760417 | 0.76 | CNR1 (0.50) | GAAMAPTKDM4EHTR1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035347-A1 | AROMATIC BYCYCLIC DERIVATIVES AS CXCR4 RECEPTOR MODULATORS | ALLERGAN, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20120295973-A1 | METHODS AND COMPOSITIONS OF DERIVATIVES OF PROBUCOL FOR THE TREATMENT OF DIABETES | SALUTRIA PHARMACEUTICALS LLC | 2012-11-22 | — | — | US | disclosed |
| US-8252840-B2 | administering monoesters of probucol, such as AGI-1067, succinobucol | SALUTRIA PHARMACEUTICALS LLC (US) | 2012-08-28 | — | — | US | disclosed |
| US-20080280979-A1 | Methods and Compositions of Derivatives of Probucol for the Treatment of Diabetes | CRABTREE ACQUISITION CO, LLC | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280979-A1 | Methods and Compositions of Derivatives of Probucol for the Treatment of Diabetes | PNLIP, SLC5A2, LIPC | GAA 790/4885MAPT 1773/4885KDM4E 3846/4885 |
| US-20130035347-A1 | AROMATIC BYCYCLIC DERIVATIVES AS CXCR4 RECEPTOR MODULATORS | CXCR4, CCR5, CXCL12 | GAA 3505/4885MAPT 3254/4885KDM4E 3230/4885 |
| US-20120295973-A1 | METHODS AND COMPOSITIONS OF DERIVATIVES OF PROBUCOL FOR THE TREATMENT OF DIABETES | PNLIP, SLC5A2, LIPC | GAA 790/4885MAPT 1773/4885KDM4E 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.